Value proposition

NeuraMetrix measures brain health using a digital bio-marker based on inconsistency of typing cadence.

NeuraMetrix measures brain health using a digital bio-marker based on inconsistency of typing cadence.

We developed NeuraMetrix TC (Typing Cadence) to monitor brain health without any tests or special equipment. Installed on a home computer, it captures typing cadence in milliseconds, allowing the detection of subtle changes in cognitive and motor function and calculation of a digital bio-marker. NeuraMetrix TC measures the "inconsistency"​ in typing cadence, a potential indication of onset and progression of neurodegenerative diseases.

NeuraMetrix TC is sensitive enough to detect very early changes in cognitive and motor function and measure decline/progress over time. It is passive, independent of language, culture and education and does not require tests, sensors, gross motor skills or physician interaction.

The Company completed its initial study with the Michael J. Fox Foundation's Fox Trial Finder. Researchers at leading academic institutions around the world are using NeuraMetrix TC in research programs involving ADHD, Brain Tumors, Chemo Brain, Depression, Epilepsy, Huntington's Disease, Multiple Sclerosis, Parkinson's Disease, REM Sleep Disorder and Traumatic Brain Injury. We are exploring research relationships in Alzheimer's Disease.

NeuraMetrix is working with researchers at Parkinson’s Institute and Clinical Center, Philipps-Universität Marburg (Germany), University of Ulm (Germany), Karolinska Institute (Sweden), University of Iowa, Gladstone Institutes, UCSF, Michael J. Fox Foundation, Stanford University, Sogn and Fjordane University College (Norway), University of Toronto, New York University, Vanderbilt University and Washington University.

Brain health monitoring platform, Measurement of neurocognitive and motor function, and Non-invasive brain monitor